Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

DRIPBEAT

Financiado

Cerrado

Drug repurposing for inhibiting pathogenic biofilms and potentiating the activit...

Drug repurposing for inhibiting pathogenic biofilms and potentiating the activity of antibiotics Bacterial biofilms are closely associated with chronic infections, leading to much higher tolerance to antibiotics and treatment failures. New strategies for biofilm disruption are thus urgently required. Cyclic-di-GMP, a secondar... ver más

06/03/2024

UGent

166K€

Presupuesto del proyecto: 166K€

Líder del proyecto

UNIVERSITEIT GENT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2024-03-06

MSCA-IF-2020: Individual Fellowships

I+D

Cerrada hace 4 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

UGent

166.32K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

NABATIVI Novel Approaches to Bacterial Target Identification Validat... 7M€ Cerrado

ANTIPATHOGN Identification and validation of novel drug targets in Gram... 8M€ Cerrado

PID2020-114627RB-I00 EL RECABLEADO DEL INTERACTOMA COMO UNA NUEVA VIA PARA EL DES... 255K€ Cerrado

SYSBIOFILM Systems biology of Pseudomonas aeruginosa in biofilms 100K€ Cerrado

PSEUDOTOX Integration of regulatory networks in Pseudomonas 182K€ Cerrado

AB-Biofilm Regulation of Acinetobacter baumannii biofilm formation by c... 215K€ Cerrado

Duración del proyecto: 35 meses Fecha Inicio: 2021-04-06
Fecha Fin: 2024-03-06

Líder del proyecto

UNIVERSITEIT GENT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 166K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Bacterial biofilms are closely associated with chronic infections, leading to much higher tolerance to antibiotics and treatment failures. New strategies for biofilm disruption are thus urgently required. Cyclic-di-GMP, a secondary messenger promoting biofilm formation, is a promising drug target. Only few compounds that reduce c-di-GMP levels and inhibit biofilms were identified so far, and most studies were conducted in vitro using standard medium and reference strains. In this project drugs will be repurposed for targeting c-di-GMP and biofilms to increase the antibiotic susceptibility of clinical Pseudomonas aeruginosa strains. Interdisciplinary approaches will be applied, combining next generation sequencing, gene expression pattern in synthetic sputum, protein structural modelling and computational drug docking, lung epithelial cell infection and murine model. This project will increase the accuracy of drug discovery based on c-di-GMP and significantly expand the skillset of an early career researcher with a strong background in the molecular mechanism of c-di-GMP pathway. The new knowledge in human cell culture and murine model obtained in this fellowship will be crucial for the researcher with a long-term interest in infection treatment. The host laboratory at Ghent University (UGent), a leading group in Europe investigating combination therapy against biofilms, offers an excellent atmosphere fostering both technical and transferable skills. The researcher will also benefit from the supervisor’s extensive research network and the numerous training programs provided by UGent to enhance the future career prospects. The research outputs will provide fresh insights into how genetic and environmental conditions influence c-di-GMP pathway (basic science) and how to select more appropriate compounds for biofilm treatment (applied science), and may also be subjected to clinical trials and attract industrial partners for wider applications.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores